Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (30)
  • Autophagy
    (10)
  • CDK
    (8)
  • EGFR
    (8)
  • FLT
    (16)
  • JAK
    (172)
  • NF-κB
    (7)
  • STAT
    (24)
  • Tyrosine Kinases
    (27)
  • Others
    (79)
Filter
Search Result
Results for "

jak

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    271
    TargetMol | Activity
  • Compound Libraries
    6
    TargetMol | inventory
  • Peptide Products
    3
    TargetMol | natural
  • Dye Reagents
    1
    TargetMol | composition
  • PROTAC Products
    3
    TargetMol | Activity
  • Natural Products
    27
    TargetMol | inventory
  • Recombinant Protein
    23
    TargetMol | natural
  • Isotope Products
    2
    TargetMol | composition
Pyridone 6
T3080457081-03-7
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.
  • $75
In Stock
Size
QTY
TargetMol | Citations Cited
JAK-STAT-IN-1
T786071236666-76-4In house
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
  • $195 TargetMol
In Stock
Size
QTY
JAK-IN-10
T13571916741-98-5In house
JAK-IN-10 is a JAK inhibitor that can be used for the research of dry eye disorders.
  • $79
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JAK-IN-5
T117102096999-92-5In house
JAK-IN-5 is a JAK inhibitor.
  • $197
In Stock
Size
QTY
JAK-IN-11
T12549916742-11-5In house
JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
  • $298
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JAK-IN-5 hydrochloride
T11710L2751323-21-2In house
JAK-IN-5 hydrochloride is a JAK inhibitor [1].
  • $1,620
1-2 weeks
Size
QTY
JAK-IN-27
T791102673176-36-6
JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM for TYK2, 7.7 nM for JAK1, and 629.6 nM for JAK3. Moreover, JAK-IN-27 impedes IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells with an IC50 of 23.7 nM [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK-IN-28
T791162445500-22-9
JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor with potential applicability in cancer and inflammatory disease research [1].
  • $1,520
6-8 weeks
Size
QTY
JAK-IN-26
T781892417134-93-9
JAK-IN-26 (compound 2) is an orally active Janus kinase (JAK) inhibitor with favorable pharmacokinetic properties, demonstrating potency in suppressing IFN-α2B-induced STAT3 phosphorylation in Jurkat cells, with an IC50 value of 17.2 nM [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK-IN-31
T798822597016-88-9
JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2, indicating potent activity across these targets. It is utilized in cancer research [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK 3 inhibitor IV
T246058753-54-1
JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
  • $62
Backorder
Size
QTY
JAK-IN-25
T781752127110-22-7
JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3. It also demonstrates an IC50 of 28 nM against human whole blood IL-12 (HEB IL-12) and holds potential for cancer research [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK-IN-29
T79222
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].
  • Inquiry Price
Size
QTY
JAK kinase-IN-1
T798072698389-43-2
JAK kinase-IN-1 (Example 1) is a potent inhibitor targeting the JAK family, including TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32 nM, 27 nM, and 3473 nM, respectively [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK-IN-34
T820172068766-90-3
JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3, and 1.95 nM for TYK2. It effectively reduces joint swelling while maintaining a good safety profile [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK-IN-21
T614942445499-20-5
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
  • $215
In Stock
Size
QTY
JAK/HDAC-IN-2
T78708
JAK HDAC-IN-2, a potent 2-amino-4-phenylaminopyrimidine dual-target inhibitor, effectively suppresses JAK1 2 and HDAC3 6 at nanomolar concentrations. This compound exhibits proapoptotic properties, inhibits histone deacetylation, and impedes STAT3 phosphorylation, demonstrating notable antiproliferative activity against various hematological malignancies and solid tumors [1].
  • Inquiry Price
Size
QTY
JAK-IN-30
T792352891469-99-9
JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1].
  • $125
35 days
Size
QTY
JAK-IN-33
T82018
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].
  • Inquiry Price
Size
QTY
JAK3i
T276501918238-72-8In house
JAK3i is a selective covalent inhibitor of JAK3 kinase. JAK3i reveals two distinct temporal waves of STAT5 phosphorylation and more potently targets the second wave, which is required for cell cycle progression and T cell proliferation.
  • $350
In Stock
Size
QTY
JAK3/BTK-IN-2
T98132674036-93-0In house
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTk-in-2 has the potential to treat diseases associated with abnormal JAK3 and BTK activity.
  • $1,330
6-8 weeks
Size
QTY
JAK3/BTK-IN-1
T98142674036-91-8In house
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inhibited the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.
  • $247
In Stock
Size
QTY
JAK2-IN-7
T359002593402-36-7
JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for Ba F3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0 G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1].
  • $148
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JAK2-IN-4
T117081438284-00-4
JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.
  • $1,970
8-10 weeks
Size
QTY
JAK3 covalent inhibitor-1
T117092300106-50-5
JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and demonstrating a 246-fold selectivity compared to other JAKs.
  • $2,720
10-14 weeks
Size
QTY
JAK2 Inhibitor V
T3042195371-52-9
JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JAK1-IN-4
T156062091134-35-7
JAK1-IN-4 is a selective JAK1 inhibitor (IC50s: 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively). JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM).
  • $1,670
6-8 weeks
Size
QTY
JAK3-IN-6
T54921443235-95-7
JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM
  • $34
In Stock
Size
QTY
JAK2-IN-6
T40443353512-04-6
JAK2-IN-6, a polysubstituted aminothiazole derivative, is a potent and selective inhibitor of JAK2 (ic50 at 22.86 μg/mL). Jak2-in-6 inhibits the activity of JAK2 enzymes by interfering with Jak2-related signaling pathways, thereby producing therapeutic effects on the specific disease IN which JAK2 is dysregulated, and does not show activity on JAK1 and JAK3. JAK2 is a protein involved in signaling pathways that regulate cell growth and division. Abnormal activation of JAK2 has been linked to a variety of diseases, including some types of cancer and inflammatory diseases. JAK2-IN-6 has antiproliferative activity against cancer cells.
  • $39
In Stock
Size
QTY
JAK3-IN-7
T100091263774-57-7
JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) intended for the treatment of organ transplantation rejection, graft-versus-host reaction post-transplantation, autoimmune disorders, allergic diseases, and chronic myeloproliferative disorders.
  • $700
10-14 weeks
Size
QTY
JAK1-IN-8
T358991973485-18-5
JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).
  • $39
In Stock
Size
QTY
JAK2-IN-9
T795812568842-26-0
Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM. It effectively inhibits the phosphorylation of JAK2, STAT3, and STAT5, possesses metabolic stabilities, and induces apoptosis. This compound is utilized in the study of myeloproliferative neoplasms (MPNs) [1].
  • $1,520
6-8 weeks
Size
QTY
JAK1-IN-11
T790792427608-43-1
JAK1-IN-11 (compound 11) is a potent Janus kinase inhibitor with nanomolar IC50 values of 0.02 nM for JAK1 and 0.44 nM for JAK2, demonstrating high selectivity for JAK1 over JAK2 [1].
  • Inquiry Price
8-10 weeks
Size
QTY
JAK1-IN-10
T790782416858-88-1
JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, is a potent and selective inhibitor of JAK1 [1].
  • Inquiry Price
8-10 weeks
Size
QTY
G5-7
T8742939681-36-4
JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study
  • $46
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Delgocitinib
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
  • $172
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Deucravacitinib
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12 23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
  • $64
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Ruxolitinib phosphate
T30431092939-17-7
Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1 2 inhibitor with IC50 of 3.3 nM 2.8 nM. Its selectivity for JAK1 2 is more than 130 times that of JAK3.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Ruxolitinib
T1829941678-49-5
Ruxolitinib (INCB018424) is a JAK1 2 inhibitor (IC50=3.3 2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Upadacitinib
T75031310726-60-3
Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Izencitinib
T358982051918-33-1In house
Izencitinib (JNJ-8398) is an orally active and gut-selective JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.
  • $88 TargetMol
In Stock
Size
QTY
Butyzamide
T678941110767-45-7In house
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba F3. The phosphorylation of JAK2, STAT3, STAT5 and MAPK is induced. Butyzamide has been shown to help increase platelet levels in mouse xenotransplantation trials.
  • $285
In Stock
Size
QTY
Tofacitinib
T6321477600-75-2
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3 2 1 (IC50=1 20 112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Tofacitinib Citrate
T2398540737-29-9
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1 2 3 (IC50s: 1 20 112 nM).
  • $32
In Stock
Size
QTY
Baricitinib
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9 5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
Fosifidancitinib
T386241237168-58-9
Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.
  • $89
In Stock
Size
QTY
TargetMol | Inhibitor Sale
WHI-P97 HCl
T4657L
WHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 microM in EGFR kinase inhibition assays. WHI-P97 effectively inhibited the in vitro invasiveness of EGFR-positive human cancer cells in a concentration-dependent manner.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JI069
T77672850019-35-1
JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.
  • $195
In Stock
Size
QTY
SJ1008030 formic
T77944
SJ1008030 (compound 8) formic is a selective JAK2 degrader from the PROTAC class, exhibiting efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an IC50 of 5.4 nM, and is potentially applicable for leukemia research [1].
  • Inquiry Price
Size
QTY
SJ1008030
T745802863634-96-0
SJ1008030 (compound 8), a JAK2 PROTAC, selectively degrades JAK2. It demonstrates potent activity against MHH–CALL-4 cells, with an EC50 of 5.4 nM and an IC50 of 32.09 nM. This compound holds potential for leukemia research [1].
  • Inquiry Price
Size
QTY